Replicon Platform Technology
New Cancer Therapy
VLP Therapeutics’ replicon platform is a novel gene delivery system that targets specific cells. The genes delivered by the replicon platform aim to change the features of macrophages or dendritic cells, enabling them to activate the immune system to destroy cancer cells. Macrophages and dendritic cells are known to be important to initiate immune responses. Our novel replicon gene delivery platform represents a breakthrough approach that could enhance current immune therapies.